Gilead Sciences, Inc. $GILD Shares Acquired by Edgar Lomax Co. VA

Key Points

• Edgar Lomax Co. VA increased its stake in Gilead Sciences by 84.2%, acquiring a total of 231,390 shares valued at approximately $25.9 million as of the latest reporting period.
• Several institutional investors have significantly increased their holdings in Gilead Sciences, with GAMMA Investing LLC raising their stake by an astonishing 13,891.1% in the same quarter.
• Gilead Sciences recently declared a quarterly dividend of $0.79, representing an annualized yield of 2.7%, with the payment date set for September 29th.

Edgar Lomax Co. VA raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 84.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 231,390 shares of the biopharmaceutical company's stock after purchasing an additional 105,800 shares during the period. Gilead Sciences accounts for approximately 1.6% of Edgar Lomax Co. VA's holdings, making the stock its 24th biggest holding. Edgar Lomax Co. VA's holdings in Gilead Sciences were worth $25,927,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of GILD. Nuveen LLC bought a new stake in Gilead Sciences during the first quarter worth approximately $620,415,000. GAMMA Investing LLC increased its stake in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock worth $285,761,000 after purchasing an additional 2,532,070 shares during the last quarter. Northern Trust Corp grew its stake in Gilead Sciences by 19.7% in the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after buying an additional 2,458,954 shares during the last quarter. Los Angeles Capital Management LLC grew its stake in Gilead Sciences by 422.6% in the 1st quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company's stock valued at $282,706,000 after buying an additional 2,040,261 shares during the last quarter. Finally, Royal Bank of Canada grew its position in Gilead Sciences by 30.1% in the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after purchasing an additional 2,005,863 shares during the last quarter. Institutional investors own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 28,000 shares of the company's stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares in the company, valued at approximately $13,026,263.04. This represents a 18.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $109.74, for a total transaction of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 79,500 shares of company stock worth $8,734,625 in the last quarter. Corporate insiders own 0.27% of the company's stock.

Analysts Set New Price Targets

GILD has been the topic of a number of recent analyst reports. Oppenheimer reduced their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. UBS Group increased their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and increased their price target for the company from $108.00 to $127.00 in a research note on Friday, August 8th. Finally, Royal Bank Of Canada raised their target price on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Seven equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $114.82.

Gilead Sciences Stock Down 0.5%

NASDAQ:GILD opened at $118.37 on Monday. The company has a market capitalization of $146.87 billion, a price-to-earnings ratio of 23.58, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. The stock has a 50-day simple moving average of $111.88 and a 200 day simple moving average of $108.50. Gilead Sciences, Inc. has a one year low of $72.89 and a one year high of $121.83. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same quarter last year, the company earned $2.01 earnings per share. The company's revenue for the quarter was up 1.4% compared to the same quarter last year. Sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, September 29th. Investors of record on Monday, September 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.